Last reviewed · How we verify
Lisinopril, losartan, and atorvastatin
Lisinopril, losartan, and atorvastatin is a Small molecule drug developed by NYU Langone Health. It is currently in Phase 2 development.
At a glance
| Generic name | Lisinopril, losartan, and atorvastatin |
|---|---|
| Sponsor | NYU Langone Health |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (PHASE4)
- The Canadian Prevention of Renal and Cardiovascular Endpoints Trial (NA)
- Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lisinopril, losartan, and atorvastatin CI brief — competitive landscape report
- Lisinopril, losartan, and atorvastatin updates RSS · CI watch RSS
- NYU Langone Health portfolio CI
Frequently asked questions about Lisinopril, losartan, and atorvastatin
What is Lisinopril, losartan, and atorvastatin?
Lisinopril, losartan, and atorvastatin is a Small molecule drug developed by NYU Langone Health.
Who makes Lisinopril, losartan, and atorvastatin?
Lisinopril, losartan, and atorvastatin is developed by NYU Langone Health (see full NYU Langone Health pipeline at /company/nyu-langone-health).
What development phase is Lisinopril, losartan, and atorvastatin in?
Lisinopril, losartan, and atorvastatin is in Phase 2.